Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas

Journal of Clinical Oncology

Volumn 18, Issue 22, 2000, Pages 3862-3872

  Cokgor, Ilkcan ^a   Akabani, Gamal ^a   Kuan, Chien Tsun ^a   Friedman, Henry S ^a   Friedman, Allan H ^a   Coleman, R Edward ^a   McLendon, Roger E ^a   Bigner, Sandra H ^a   Zhao, Xiao Guang ^a   Garcia Turner, Ana M ^a   Pegram, Charles N ^a   Wikstrand, Carol J ^a   Shafman, Timothy D ^a   Herndon, James E ^a   Provenzale, James M ^a   Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6; TENASCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; BEAM THERAPY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; OUTCOMES RESEARCH; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034669697     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.22.3862     Document Type: Article

References (29)

1. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
2. Recursive partitioning analysis of prognostic factors in the three radiation therapy oncology group malignant glioma trials
3. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: Prognostic factors and long-term outcome
4. Supratentorial malignant glioma: Patterns of recurrence and implications for external beam local treatment
5. Immunological studies of human gliomas
6. Monoclonal antibodies in the treatment of central nervous system malignancies
7. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure
8. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies
9. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results
10. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas
11. Antibodies and molecular immunology: Immunohistochemistry and antigens of diagnostic significance - Chapter 8
12. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis
13. Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration
14. 131I radiolabeled murine monoclonal antibody in a human glioma xenograft model
15. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: Comparison of intracarotid and intravenous administration
16. 2: A preliminary report
17. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: The Polymer-Brain Tumor Treatment Group
18. Dosimetry and dose-response relationships in newly diagnosed patients treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy
19. Dosimetry of I-131 labeled 81C6 monoclonal antibody administered into surgically created resection cavities in malignant brain tumor patients
20. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
21. 131I monoclonal antibody: Feasibility, pharmacokinetics and dosimetry
22. Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors
23. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates
24. An analysis of dose-effect relationship in radiotherapy of malignant gliomas
25. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme
26. Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas
27. Stereotactic radiosurgery as primary adjuvant treatment for glioblastoma: The JCRT update
28. A randomized trial of interstitial radiotherapy (RT) boost for newly diagnosed malignant glioma: Brain Tumor Cooperative Group (BTCG) Trial 8701